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A significant proportion of critically ill patients with 
severe AKI, particularly those who develop refractory 
complications [1], receive support with renal-replace-
ment therapy (RRT) [2]. There has been a longstanding 
dilemma on when RRT should be started for patients 
with severe AKI, specifically among those without AKI-
related complications that could be addressed by RRT. 
Among patients with urgent or refractory complications, 
there is consensus for starting RRT. However, should 
RRT be started earlier in the course of AKI to pre-empt 
complications or judiciously delayed and started if and 
when complications arise? Furthermore, clinicians are 
challenged to select those patients who will have high 
probability of clinical benefit (restore metabolic/fluid 
homeostasis) and improved outcome (survival, recovery, 
quality of life) and to avoid RRT in patients who do not 
need it, will not benefit from it or who have greater prob-
ability of experiencing harm from it.
Several randomized trials have shown that an ear-
lier strategy for starting RRT does not confer a sur-
vival advantage, can increase the risk of harm (dialysis 
dependence [3], bacteremia [4]) and portend greater 
resource use compared with a “watch-and-wait” or 
delayed strategy [3–5]. These trials now support the 
broad notion that deferral of RRT, pending the devel-
opment of urgent indications, should be adopted as the 
default strategy. The rationale for a “watch-and-wait” 
approach is to provide opportunity to observe for recov-
ery and to avoid RRT in selected patients [3–5]. However, 
the variables that define “deferral” remain uncertain. Spe-
cifically, when confronted with patients who have severe 
and non-resolving AKI, for how long can deferral be 
considered safe and acceptable? This was addressed by 
the recent Artificial Kidney Initiation in Kidney Injury-2 
(AKIKI-2) trial [6].
AKIKI-2 was a multi-centre trial comparing two strate-
gies for delayed RRT initiation in 278 patients. Similar to 
AKIKI, patients fulfilled criteria for Stage 3 AKI and were 
receiving either mechanical ventilation and/or vasopres-
sors. However, where AKIKI-2 differed is that eligibility 
specified a protracted AKI course, defined by oligo-anu-
ria for ≥ 72 h and/or a serum urea 40–50 mmol/L (112–
140 md/dL). Upon fulfilling these criteria, patients were 
randomized to “delayed” RRT (aligned with the delayed 
strategy of AKIKI [4]) started within 12  h of randomi-
zation or “more-delayed” RRT, defined by deferring 
RRT until an urgent indication emerged or serum urea 
exceeded 50 mmol/L (140 md/dL). Oligo-anuria was not 
a trigger for RRT in the more-delayed strategy. The pri-
mary outcome was “days-alive and RRT-free” from rand-
omization through 28 days, conditional on patients being 
alive and RRT free for 3-consecutive days.
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Fig. 1 Proposed algorithm for starting renal‑replacement therapy for critically ill patients with moderate‑to‑severe acute kidney injury 
(adapted from [13, 14]). *Urgent indications include fluid overload (PaO2/FiO2 < 200 plus clinical perception); metabolic acidosis (pH < 7.20 or 
 HCO3− < 12 mmol/L; hyperkalemia  (K+  ≥ 6.0 mmol/L); and/or complications attributable to uremia (bleeding; encephalopathy; pericarditis)
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RRT-free days did not differ between the strategies. 
There were also no differences in secondary endpoints, 
including ventilator-free days, ICU stay or kidney 
recovery. In a pre-specified analysis, allocation to the 
more-delayed strategy was found to increase the hazard 
of death (adjusted-HR 1.65) compared with the delayed 
strategy.
Inherent in the AKIKI-2 design, it was hypoth-
esized that the more-delayed strategy would increase 
in RRT-free days. It is therefore notable that RRT-free 
days were not greater with the more-delayed strategy, 
despite fewer patients receiving RRT and when initi-
ated, occurring ~ 2 days later, when compared with the 
delayed strategy. As such, the likely driver of the pri-
mary outcome was higher mortality with the more-
delayed strategy. This could have plausibly been driven 
by several factors, such as the effects of prolonged 
untreated AKI, exaggerated non-renal organ dysfunc-
tion (e.g., delirium [7]) and modified recovery from 
critical illness [8]. The protocol embedded precautions 
to prevent intra-dialytic hypotension and dialysis-
disequilibrium syndrome, but these events were not 
reported. Finally, small and unblinded trials would be 
susceptible to biased co-interventions, such as with-
drawal of life-sustaining treatments.
AKIKI-2 is applicable to a small proportion of patients 
with AKI. Of the 5,336 patients screened, only 767 
(14.4%) fulfilled the initial eligibility. Of the 4,466 ini-
tially excluded, 42.9% failed to achieve Stage 3 AKI and 
many were excluded for urgent indications (13.5%) or 
prior RRT (6.8%). Moreover, of those with Stage 3 AKI 
who were excluded, 127 (26.0%) developed an urgent 
indication after a median (IQR) of 35 (17–68) hours and 
received RRT, while the remainder did not fulfil randomi-
zation criteria.
Similar to AKIKI, AKIKI-2 again suggests that serum 
urea as a primary trigger is not ideal for identification of 
the optimal timing of RRT, regardless of the thresholds 
evaluated [9]. First, serum urea was not useful for iden-
tifying patients with an increased mortality risk [10]. We 
currently lack robust data on serum urea thresholds that 
constitute toxicity. Rather than a specific threshold, the 
duration of elevated serum urea may be a better surro-
gate for the development of uremic-related complica-
tions. Second, serum urea is influenced by a range of 
factors other than impaired excretion, including excess 
protein catabolism, corticosteroid administration, exog-
enous protein or gastrointestinal bleeding and volume 
contraction. Finally, the thresholds of serum urea did not 
discriminate patients with urgent indications for RRT: 
16.6% of Stage 3 AKI patients had urgent indications 
developed prior to the delayed criteria being fulfilled, and 
33% of patients in the more-delayed strategy developed 
urgent indications prior to the protocolized serum urea 
threshold (> 50 mmol/L) was fulfilled.
AKIKI-2 highlights the need for robust and validated 
tools that discriminate between patients with AKI who 
are most likely to need and benefit from starting RRT 
from those in whom it can or should be avoided. Such 
tools include clinical prediction by machine learning [11], 
predictive enrichment with AKI sub-phenotypes, use of 
the furosemide stress test and emerging biomarkers of 
persistent severe AKI [12].
Conclusions
Recent evidence has shown that pre-emptive or earlier 
RRT in patients with severe AKI and no urgent indica-
tions does not confer clinical benefit. By default, this 
would imply that a more judicious “watch and wait” 
strategy is acceptable. The findings of AKIKI-2 reinforce 
that there are limitations and harm to protracted delays 
in RRT initiation in patients with severe and persistent 
AKI [6]. Clinicians are bound to remain challenged by a 
lack of clarity on the optional circumstances to initiate 
RRT until additional evidence emerges. In the mean-
time, such uncertainty should not negate the importance 
of sound patient-centred practice grounded in the avail-
able evidence (Fig. 1). Clinicians should integrate an indi-
vidual patient’s evolving critically illness, their dynamic 
response to interventions, the trajectory of AKI and like-
lihood for recovery, and importantly, patient and family 
preferences for care.
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